Fluconazole (DBL) is a medicine containing the active ingredient(s) fluconazole. On this page you will find out more about Fluconazole (DBL), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: fluconazole
Information for medicine and pack size:
Fluconazole (DBL) 150 mg hard capsule, 1
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin B. [Note. Data suggests that the clinical efficacy of fluconazole is lower than that of amphoterericin B in the treatment of the acute phase of cryptococcal meningitis.] Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS. Treatment of oropharyngeal and oesophageal candidiasis in AIDS and other immunosuppressed patients. Secondary prophylaxis of oropharyngeal candidiasis in patients witth HIV infection. Serious and life-threatening Candida infections in patients who are unable to tolerate amphotericin B. [Note. It remains to be shown that fluconazole is as effective as amphotericin B in the treatment of serious and life-threatening candida infections. Until such data are available, amphotericin B remains the drug of choice.] Vaginal candidiasis, when topical therapy has failed. Treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. Usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks (see Adverse Effects).
Table of characteristics
|Visual appearance||Hard gelatin capsule with opaque green head and body.|
|Dosage Form||Capsule, hard|
|Route of administration||Oral|
1 capsule, blister pack: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||No information available|
|Life time||5 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.